targets for the development of novel therapies in patients with the most aggressive disease phenotypes.
Mutations in NF1, NRAS, KRAS, PTPN11 and CBL ('RAS pathway' mutations) currently allow for a molecular diagnosis in 85% of patients [7] [8] [9] [10] [11] . Recently, secondary mutations in SETBP1 and JAK3 were identified by whole-exome sequencing in a small number of patients with JMML at diagnosis 12 . We subsequently identified several patients who had increased allele frequency for SETBP1 mutations at relapse. We then used droplet digital PCR (ddPCR) to show that subclonal SETBP1 mutations were present in nearly one-third of patients with JMML at diagnosis and independently predicted relapse 13 . These findings indicated a level of genetic complexity previously unrecognized in JMML, and, given the limited numbers of patients with non-syndromic, de novo JMML who have had exome sequencing performed, we set out to assess the genomic landscape of JMML. We sequenced samples from patients (n = 29) with matched tumor-normal pairs. Seven of these patients also had serially acquired samples from relapse and/or transformation to acute myeloid leukemia (AML) available for sequencing. We then validated our findings in an independent cohort of 71 patients ( Supplementary Fig. 1 ), of whom nine had paired diagnostic-relapse samples available. Two of the 29 patients who had exome sequencing data were suspected of having Noonan syndrome. Upon confirmation of this diagnosis, these patients were removed from all outcome analyses, which were specific to patients with somatically mutated JMML.
RESULTS

Sequencing of JMML samples using optimized algorithms
We performed whole-exome sequencing at a mean coverage of 95× ( Supplementary Table 1 ) for 22 patients with paired germline-diagnosis samples and an additional seven patients with germline-diagnosis-relapse samples (Fig. 1) . Because of the frequent contribution of germline mutations in the development of JMML 7, 11 , we optimized an algorithm to detect tumor in normal content (deTiN) to retrieve mutations that would otherwise have been missed using a traditional tumor-normal bioinformatics approach. Four tissue types of germline material were used as normal controls, including buccal cells, cord blood, Epstein-Barr virus (EBV)-immortalized lymphoblasts and fibroblasts. However, by comparing several within-patient germline sources that contained varying degrees of tumor content, it became evident that each tissue type had different amounts of tumor contamination in the normal sample. For example, in patient UPN2026, we first detected a heterozygous mutation in RRAS2 in DNA from a buccal swab, but repeat sequencing of EBV-immortalized B cells showed wild-type sequence (Supplementary Fig. 2) . We therefore implemented deTiN to both assess and correct for the purity of each germline source.
In total, we identified ten genes that were mutated beyond the five RAS pathway genes previously documented to have lesions (Supplementary Table 2 ). The mutations occur in known oncogenes and tumor suppressors that broadly fall into categories of genes affecting the RAS pathway, signal transduction, transcription factors, epigenetic regulation and the spliceosome complex ( Fig. 1 and Table 1 ).
We next carried out targeted deep sequencing (mean coverage of 1,380×) on 71 diagnostic tumors as well as paired diagnostic-relapse samples from nine patients for the 15 genes identified by exome sequencing to determine the frequency of mutations in these genes. In addition, we sequenced JAK3, as previous reports had identified recurrent subclonal mutations in this gene in some patients. We also included 11 patients from the discovery cohort in the resequencing cohort for validation purposes. All pathogenic mutations identified by exome sequencing were identified by targeted resequencing. Recurrent mutations were detected in 14 of the 15 genes, excluding RRAS2, for which mutations were only identified in the discovery cohort (Supplementary Table 3 ). The incidence of mutations in these genes is presented for a total of 100 patients, of whom 29 were in the discovery cohort and 71 were in the validation cohort ( Supplementary Fig. 3 ). RNA sequencing (RNA-seq) data were available for 14 patients (15 samples) and confirmed that each of the pathogenic variants detected in exome and deep sequencing was transcribed and present in the RNA ( Supplementary Table 4 ).
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A r t i c l e s
Somatic copy number alterations
The most common karyotypic abnormality identified in whole-exome sequencing was deletion of one copy of chromosome 7, which occurred in five of the exome-sequenced cases (Supplementary Fig. 4 ).
One patient with t(11;17) detected by diagnostic cytogenetics had additional evidence of disruption of the NF1 locus in FISH analysis (data not shown) and was found to have a germline mutation in this gene by whole-exome sequencing. The NF1 allele harboring the c.2041C>T mutation had a fractional abundance of 33% in RNA transcriptome sequencing (15/45 reads). However, RNA-seq did not identify a fusion transcript in this patient, suggesting that the translocation breakpoints might be intergenic. RNA-seq in 14 additional patients did not identify any structural rearrangements resulting in chimeric transcripts. Consistent with previous reports 14, 15 , the only additional recurrent structural variants were copy-neutral isodisomy at 11q23.3 and 17q11.2 where CBL and NF1 are located, respectively ( Supplementary Fig. 5 ).
Expanding the spectrum of RAS pathway mutations
In addition to canonical NF1, KRAS, NRAS, PTPN11 and CBL alterations, we identified a previously described RRAS mutation in one patient 16 , as well as an RRAS2 alteration in another patient, neither of whom harbored other driver mutations at diagnosis. Mutations in RRAS2, a member of the RAS GTPase superfamily encoding the TC21 oncoprotein, have previously been limited to solid malignancies, including ovarian, endometrial and squamous cell carcinomas 17 , and regulate transforming growth factor (TGF)-β signaling through loss of NF1 (ref. 18 ). The RRAS2 point mutation in one of our patients results in the p.Gln72Leu amino acid substitution that was previously shown to confer transformative properties in ovarian tissue, as evidenced by increased colony formation in vitro and increased tumorgenicity after inoculation in mice as compared to wild-type RRAS2 (ref. 19) .
Although RAS pathway lesions have traditionally been thought to represent largely mutually exclusive events 20 , coexisting mutations in NRAS, KRAS, PTPN11, CBL and NF1 were found in 11 of 100 (11.0%) patients ( Fig. 2) . Analysis of single colonies for two patients with compound RAS pathway mutations demonstrated that both mutations occurred in the same colony ( Supplementary Table 5 ). PTPN11 and 
NF1 lesions were the most frequent of these cooperative events. In addition, one patient harbored two NRAS lesions (encoding p.Gly13Asp and p.Gln61Lys substitutions).
NF1 mutations in patients without clinical NF1
Two patients in our discovery cohort who were not suspected of having neurofibromatosis type 1 (NF1) nevertheless harbored germline NF1 mutations. One of these patients was heterozygous for the mutation in both the tumor and matched normal (buccal cell) samples, with no LOH noted in the tumor. Another patient had an NF1 mutation with an allelic fraction of 10.1% in the germline tissue sample (buccal cells). The allelic fraction in the tumor increased to 45.3% after a copy-neutral duplication at 17q. Although an event with low allelic fraction in germline tissue could be explained as a somatic-only variant in tumor contamination of the normal sample, application of the deTIN algorithm estimated that no such contamination occurred (95% confidence interval (CI) for contamination = 0-3.35%), on the basis of absence of the copy number alteration in the normal tissue sample. This finding raises the possibility of somatic mosaicism, which occurs in clinical NF1 and often presents with subtle clinical features 21 . In our validation cohort, an additional six patients harbored NF1 mutations, but only three were suspected of having clinical NF1. It is not possible to determine the somatic versus germline origin of these lesions, as germline tissue was not available for these patients. These observations are consistent with a previous study indicating that JMML can be the first manifestation of NF1 in some affected infants and young children 22 .
Activated JAK-STAT corresponds with poor clinical outcome
We previously found that increased STAT5 phosphorylation in a subset of myeloid cells is a general feature of JMML 23 . The tumor suppressor LNK is encoded by SH2B3 and negatively regulates JAK-STAT signaling 24 . Mutations in SH2B3 were first reported in a variety of adult MPNs, including primary myelofibrosis and essential thrombocythemia, as well as in isolated erythrocytosis [25] [26] [27] . The alterations included nonsense and missense mutations affecting the pleckstrin homology (PH) domain and/or the Src homology 2 (SH2) domain. Mutations in SH2B3 have also been identified in lymphoid malignancies, including acute lymphoblastic leukemia, as both germline and somatic events 28 . Two patients in the discovery cohort possessed compound heterozygous mutations in SH2B3 in addition to a known JMML driver mutation. Each patient had a nonsense mutation mapping to both the PH domain and the SH2 domain ( Fig. 3a) . Whereas one patient harbored these mutations at diagnosis, the other patient only had detectable SH2B3 mutations upon transformation to AML. The latter patient relapsed with AML 3 years after his initial diagnosis. Protein lysates collected from unsorted primary mononuclear cells from these patients showed a decrease in LNK amount by immunoblot, commensurate with the allelic fraction of the patients' nonsense mutations (Fig. 3b) . One additional patient without any other identifiable mutations was found via exome sequencing to harbor a germline SH2B3 mutation encoding p.Glu400Lys, corresponding to a nonsynonymous SNP that has previously been associated with idiopathic erythrocytosis 29 .
In the validation cohort, an additional four patients were found to harbor SH2B3 mutations, for a cumulative incidence of 7.0% (7/100) ( Supplementary Table 3 ).
We did not identify any activating JAK3 mutations in our exome discovery cohort, but we performed resequencing with improved coverage (680×) in our validation cohort, given previous reports 12 . These studies uncovered JAK3 mutations in six of 83 cases (7.3%). Of note, three of the four patients with JAK3 mutations at diagnosis went on to relapse. Two other patients had lesions detected only at relapse (with allelic fractions of 8.6% and 37.4%) and presumably had subclonal mutations at diagnosis below the threshold of detection by our exome sequencing.
SETBP1 mutations are frequently subclonal at diagnosis
We detected a similar incidence of SETBP1 mutations (7/100; 7.0%) using deep sequencing as was previously reported by Sakaguchi et al. 12 . An additional 17 patients were found to harbor subclonal SETBP1 mutations using ddPCR 13 . In combination, subclonal and clonal SETBP1 mutations occurred in 24 of the 100 patients ( Supplementary Table 6 ). No mutations were found by exome sequencing in ETNK1, a gene that was recently reported to have mutations co-occurring with ones in SETBP1 in atypical chronic myelogenous leukemia (aCML) 30 .
Transcription factor mutations in JMML
We identified mutations in GATA2 (ref. 31 ), a transcription factor broadly involved in hematopoiesis. Recent work has shown that germline GATA2 mutations are responsible for several syndromes, leading to a predisposition to myeloid malignancies and opportunistic infections [32] [33] [34] . Two patients harbored three heterozygous mutations, all of which affected the regulatory zinc-finger (ZF1) domain. The overwhelming majority of mutations occurring in previous reports affected either the ZF1 or ZF2 domain [34] [35] [36] . One of our two patients harbored both a germline and a somatic GATA2 mutation, as previously described 37 . The other patient was found to have a somatic variant encoding p.Asn317Ser on one allele, which has previously been detected in patients with both myelodysplastic syndrome (MDS) and AML 38, 39 .
A heterozygous nonsense RUNX1 mutation was also found in one patient at diagnosis and in another patient at relapse, representing the first reports, to our knowledge, of haploinsufficient RUNX1 mutations in JMML 40 . Haploinsufficient missense mutations in RUNX1 have previously been reported in other malignancies such as MDS and AML and are predicted to be inactivating 41 .
Wiskott-Aldrich syndrome mutations in JMML
Previous reports have documented germline WAS mutations in patients suspected of having JMML 42, 43 . Similarly, we detected one male patient with a germline WAS mutation encoding p.His180Asn that has been described in several patients with Wiskott-Aldrich syndrome 44 . Interestingly, this patient also had a somatic NRAS mutation encoding p.Gly12Ser. To the best of our knowledge, there are no previous reports in the literature of patients with concomitant germline mutations in WAS and somatic mutations in RAS pathway genes.
Mutations in epigenetic modifiers are frequent in JMML
In contrast to previous reports that emphasized the rarity of genetic mutations in epigenetic modifier genes in JMML [45] [46] [47] , we identified 
Figure 2
Circos plot of samples with at least two mutations. Using data from whole-exome sequencing and targeted resequencing, patients with at least two mutations are depicted. Associations between genomic alterations in the same patient are marked by connecting bands, with the width of each band proportional to the frequency of the association. such mutations in 14 of the 100 patients, for a combined incidence in our cohort of 14.0%. Components of PRC2, including EZH2 (4/100; 4.0%) and ASXL1 (8/100; 8.0%), were mutated at diagnosis, and tumor cells with these mutations were clonally expanded in several patients at relapse (Supplementary Tables 2 and 3) . All four patients with mutations in EZH2 (7q36.1) also had monosomy 7 (Fig. 2) . We also found DNMT3A mutations in three patients, including one mutation that affected the previously reported Arg882 hotspot and two other frameshift mutations. Genome-wide DNA methylation analysis demonstrated that four of the five patients with ASXL1 mutations had a globally hypermethylated profile in comparison to patients with wild-type ASXL1 ( Supplementary  Fig. 6 ), whereas one patient with a DNMT3A mutation had a globally hypomethylated profile, consistent with previous reports 48, 49 .
The spliceosome complex is implicated in JMML
A member of the spliceosome complex, ZRSR2, was mutated in one patient in our discovery cohort as well as in two additional patients upon targeted resequencing. A pairwise analysis was carried out comparing RNA-seq data from one patient with a ZRSR2 mutation and 14 patients wild type for ZRSR2. The patient with mutant ZRSR2 had increased retention of U12-type introns in comparison to those with wild-type ZRSR2, consistent with previous reports in adults with MDS 50 (Supplementary Fig. 7) . To our knowledge, these are the first reported ZRSR2 mutations in JMML 47, 51, 52 . No mutations in SF3B1, U2AF1 or SRSF2 were found in our discovery phase.
Phylogenetic evolution at relapse
Focusing on patients with both diagnostic and relapse material allowed us to plot the acquisition of mutations over time ( Supplementary Fig. 8 and Supplementary Tables 2 and 3 ). All of the pathogenic mutations at diagnosis were present at relapse. However, it should be noted that, owing to the low number of mutations per sample (0.468 mutations/Mb), these analyses lacked the power to definitively track clones over time.
To further investigate the clonality of the mutations at diagnosis, we analyzed individual colonies obtained from diagnostic colony-forming unit (CFU) granulocyte-macrophage assays ( Supplementary Table 7 ). Patients UPN1420 and UPN2531 were particularly interesting because of the pattern of SH2B3 mutations detected. UPN2531 harbored a PTPN11 driver mutation along with compound heterozygous mutations in SH2B3 at diagnosis. By contrast, UPN1420 only acquired mutations in SH2B3 upon transformation to AML (Supplementary Fig. 9a ).
Colonies from UPN1420 were homozygous for either the p.Gln258* (19/24) or p.Phe390fs (5/24) alteration. In a model of convergent evolution, these clones were likely the result of copy number alterations occurring at 12q in individual cells that contained heterozygous SH2B3 mutations. Copy number variation analysis of this sample at relapse showed distinct duplication and loss at 12q where SH2B3 resides ( Supplementary Fig. 9b ). We hypothesize that the allele with the mutation encoding p.Gln258* was duplicated in one clone whereas the mutation encoding p.Phe390fs achieved homozygosity in the other.
Clinical and biological features at diagnosis
A total of 98 of the 100 children with JMML diagnosed between 2001 and 2013 at North American institutions were included in our analysis, with two patients excluded because of an underlying diagnosis of Noonan syndrome ( Supplementary Table 8 ). Zero or one somatic alteration (pathogenic mutation or monosomy 7) was identified in 64 (65.3%) patients at diagnosis, whereas two or more alterations were identified in 34 (34.7%) patients (mean number of alterations = 1.32, range = 0-4). Several clinical and biological characteristics showed statistically significant differences when compared between these groups ( Supplementary Table 9 ). A higher proportion of patients diagnosed with two or more alterations were older (P < 0.001) and male (P = 0.001). These patients also demonstrated a higher rate of monosomy 7 (P < 0.001) or somatic NF1 mutation (P < 0.001).
Somatic alterations at diagnosis predict outcome
Using the number of somatic events at diagnosis, we evaluated differences in event-free survival and overall survival. We initially identified a trend toward improved outcome in patients with zero or one somatic alteration in comparison to those with two or more alterations in our 27-patient exome cohort (P = 0.12) (Supplementary Fig. 10a ). This trend was later validated in our independent cohort of 71 patients (P = 0.0004) (Supplementary Fig. 10b ). Combining both cohorts (98 patients in total), patients with zero or one somatic alteration at diagnosis had improved outcomes in comparison to patients who had two or more alterations (event-free survival hazard ratio (HR) = 2.09, P = 0.009; overall survival HR = 2.02, P = 0.018). The 10-year eventfree survival and overall survival rates according to number of somatic events at diagnosis were as follows (± standard error): zero or one alteration, 60.6 ± 6.2% and 65.1 ± 6.0% and two or more alterations, 22.7 ± 7.4% and 29.0 ± 8.3% (P = 0.003 and 0.002, respectively; Fig. 4a,b) . Log-rank tests detected statistically significant differences in times to both outcomes on the basis of this predictor variable. Differences in event-free and overall survival for groups stratified by canonical RAS pathway driver alteration, including ones in PTPN11, NF1, NRAS, KRAS and CBL, were not statistically significant in our cohort (P = 0.834) ( Supplementary Fig. 11 ). Of note, event-free survival for patients with two RAS pathway mutations (14%; n = 7) in our cohort was significantly inferior to that for patients with a single RAS pathway mutation (62%; n = 55) (P = 0.017). This difference in outcome implies a dosage effect based on the number of RAS mutations and suggests that each mutation in a pair of compound RAS mutations has biological activity. Previous studies have assigned poorer prognostic significance to several clinical and laboratory characteristics in patients with JMML, including older age, male sex, lower platelet count, higher fetal hemoglobin concentration, monosomy 7, PTPN11 mutation and subclonal SETBP1 mutation. In univariate Cox analyses ( Supplementary  Table 10 ), the only characteristic that reached significance for event-free and overall survival was age of ≥24 months (HR = 2.09, CI = 1.20-3.62, P = 0.009 and HR = 2.03, CI = 1.13-3.66, P = 0.018). Notably, the most statistically significant covariate in this analysis was the number of somatic alterations at diagnosis (event-free survival HR = 2.65, CI = 1.27-5.54, P = 0.01 and overall survival HR = 3.13, CI = 1.39-7.01, P = 0.006). Furthermore, when a Cox multivariate regression model was applied, only the number of somatic alterations at diagnosis retained statistical significance for both event-free and overall survival. Two or more somatic events remained independently prognostic of poor outcome (HR = 2.86, CI = 1.35-6.05, P = 0.0006 and HR = 3.00, CI = 1.27-8.40, P = 0.0008) after adjusting for age, platelet count, fetal hemoglobin concentration and NF1 status at diagnosis ( Table 2) .
We assessed the relapse incidence in patients who were treated with HSCT. Of the 79 patients in our cohort who received HSCT and had follow-up data, 49 (62%) harbored zero or one alteration at diagnosis in comparison to 30 (38%) who harbored two or more alterations. As expected, the cumulative incidence of relapse from the time of HSCT was significantly higher in the cohort with two or more events at diagnosis (77.7 ± 8.56%) than in the cohort with zero or one event (38.4 ± 8.33%; log-rank P = 0.0002) (Supplementary Fig. 12 ).
DISCUSSION
Although previous genomic and biochemical analyses in JMML have emphasized dependence on the RAS pathway for initiation of disease 12 , we hypothesized that additional pathways might be important for both disease initiation and progression. By studying patients with progressive disease and by optimizing the use of germline controls, the mutational spectrum in JMML is now expanded to include some molecules with 'off-the-shelf ' therapeutic implications, whereas others will require further investigation. In addition to identifying another member in the RAS family of oncogenes mutated in JMML (RRAS2), we also uncovered additional genetic pathways contributing to leukemogenesis, including upregulated JAK-STAT signaling and epigenetic modification through the PRC2 and spliceosome complexes.
This report is the first to our knowledge to identify SH2B3 mutations in JMML. In combination with a previous study that uncovered missense JAK3 alterations 12 , these data raise the possibility of using JAK inhibitor therapy in the subset of patients harboring these mutations. This is also the first report of ZRSR2 mutations in this disease.
In contrast to chronic myelomonocytic leukemia (CMML), where epigenetic mutations are frequent 53 , previous reports in JMML have focused on the rarity of these events. However, 14% of patients in our cohort harbored genetic alterations in epigenetic modifier genes. We show that ASXL1 mutations result in globally hypermethylated profiles. Patients exhibiting aberrant methylation would be predicted to respond to DNAhypomethylating agents, and previous case reports support the notion that these agents have clinical usefulness in JMML 54 . Currently, a phase I/II trial using 5-azacytidine in children with JMML is enrolling patients in Europe. Mutations in DNMT3A typically cause decreased methyltransferase activity and result in focal areas of CpG hypomethylation 55 .
Obtaining germline tissue in children was of critical importance in our study because approximately 25% of patients had inherited syndromes that predispose to the development of JMML. In addition, unlike in other hematological malignancies, where one can use remission bone marrow samples for germline tissue, patients with JMML rarely respond to traditional chemotherapy before transplantation 56 . By developing innovative algorithms to identify tumor in normal (TiN) content with retrieval of minor differences in tumor-normal comparisons, we identified several variants that would have otherwise been overlooked using standard approaches. We showed that sources such as buccal swabs, cord blood and EBV-immortalized lymphocytes were all suboptimal in comparison to bone marrow fibroblasts. Although buccal samples are frequently contaminated with tumor by infiltrating leukemic cells, cord blood and EBV-immortalized samples provided biological insights into disease.
In the majority of cord blood samples, the canonical mutation was retrievable, reflecting the in utero nature of leukemic initiation 57, 58 . Of note, the mean age at diagnosis of the five patients who had cord blood available was 6.6 months. Interestingly, no secondary mutations were identified at diagnosis in any of these children, which may explain why younger age at diagnosis has traditionally been a more favorable clinical risk factor for outcome. B cells immortalized with EBV also provide insights into the range of the hematopoietic lineages affected by JMML mutations, with many patients appearing to have clonal involvement of mutations in the B cell compartment, whereas others only had myeloid cell involvement. There were insufficient patients available to determine how frequently such involvement occurs.
Several mutated genes new to JMML were identified in relapse samples, including RUNX1 and JAK3. However, in contrast to most malignancies, where a branching model of disease evolution with mutation acquisition and dropout is common 59 , JMML appears to have a unique model of progression. Specifically, mutations identified at diagnosis invariably persisted at relapse in all 16 patients analyzed over time. In addition, the cancer cell fraction for mutations identified at diagnosis by exome sequencing approached 100%, implying that all mutations occurred within a single dominant clone. Singlecolony analysis in three patients with available cryopreserved cells was consistent with a linear model of acquisition for additional genetic features ( Supplementary Fig. 9 and Supplementary Tables 5 and 7) . When developing new therapeutic strategies for these patients, it will be critical to understand how secondary mutations alter the behavior of cells in contrast to cells harboring only the primary lesion. Indeed, combinatorial therapies with agents that target the RAS pathway as well as the secondary genetic event may be necessary, as our work demonstrates that the clone harboring the secondary event frequently expands at disease progression. For example, combining a MEK inhibitor with DNA-hypomethylating agents could prove more efficacious in the correct genetic context than monotherapy with a MEK inhibitor 60, 61 .
Previous reports have reached different conclusions regarding the prognostic relevance of canonical RAS pathway mutations in JMML 5, 6 . We show that mutations in the five RAS pathway genes are not independently prognostic of outcome, precluding their sole use in a risk stratification algorithm. Consistent with our hypothesis, we found that the number of mutations at diagnosis, rather than the type of mutations, possesses prognostic relevance.
In conclusion, we demonstrate that patients with JMML who harbor two or more somatic alterations at diagnosis have significantly worse event-free and overall survival rates than those with one or no event. In previous reports that identified older age, male sex and lower platelet count as markers of poor outcome, these clinical features were likely descriptors of patients with two or more underlying somatic alterations. Notably, in addition to identifying patients with aggressive disease, our expanded mutational spectrum will serve as a platform for studying the interactions of these secondary events in the context of hyperactive RAS-mitogen-activated protein kinase (MAPK) signaling. These studies will allow further interrogation of multiple molecular targets that can be exploited in patients predicted to have poor outcomes using conventional HSCT.
URLs. Exome Aggregation Consortium (ExAC), http://exac.broadinstitute. org/; DesignStudio, http://designstudio.illumina.com/.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Patients. Twenty-nine patients diagnosed with JMML were included in the discovery cohort and had germline-tumor pairs evaluated by whole-exome sequencing. Seven of these patients also had relapse samples included in the exome analysis (Supplementary Table 1) . A validation cohort comprising 71 distinct patients was tested for the 16 genes found to be mutated (including JAK3, for which we did not identify lesions by exome sequencing) during the discovery phase. Ninety-eight patients with JMML confirmed on the basis of internationally accepted criteria 62 were included in the survival analysis. In addition to date of diagnosis, follow-up and sequencing data, 12 potential clinical and laboratory prognostic factors were analyzed (Supplementary Table 8 ). Ten of these patients had relapse tissue included in targeted resequencing. Fifty of the validation cohort samples were from patients who were enrolled in clinical trial AAML0122, which evaluated the safety and efficacy of a farnesyltransferase inhibitor as a window treatment before HSCT 63 . Eleven of the 81 validation samples were previously included in the discovery cohort. Fourteen patients from the combined cohorts also had RNA-seq performed. Twelve patients had genome-wide DNA methylation analysis performed. Approvals for these studies were obtained from the University of California San Francisco (UCSF) Committee on Human Research. All participants or their guardians provided informed consent in accordance with the Declaration of Helsinki.
Tissue. Germline DNA was extracted using standard methods from buccal swabs, cord blood, skin fibroblasts, bone marrow fibroblasts or EBV-immortalized cell lines, as available. Tumor DNA was extracted using standard methods from bone marrow or peripheral blood mononuclear cells obtained at diagnosis and at relapse, when available. RNA was extracted using a TRIzol chloroform method.
Discovery. Whole-exome sequencing was performed using the Illumina platform as described previously. In brief, DNA was fragmented by sonication (Covaris) to 150 bp in size and further purified using Agencourt AMPure XP beads. Size-selected DNA (50 ng) was then ligated to specific adaptors during library preparation (Illumina TruSeq). Each library was constructed with sample-specific barcodes and quantified by quantitative PCR (Kapa Biosystems), and two libraries were pooled for a total of 500 ng for exome enrichment using the Agilent SureSelect hybrid capture kit (Whole Exome_v1.1, Agilent Technologies). Several captured libraries were pooled further and sequenced on one or more lanes to a final equivalent of two exomes per lane on a HiSeq 2500 instrument (Illumina).
Calling of somatic variants, germline variants, and small deletions and insertions was performed within the Firehose environment at the Broad Institute with the previously published MuTect 64 , Haplotype 65, 66 and Indelocator 67 . In addition, we manually reviewed all candidate driver events using the Integrative Genomics Viewer. Genome-wide copy-ratio profiles were inferred using CAPSEG 68 . Read depth at capture targets in tumor samples was calibrated to estimate copy ratio using the depths observed in a panel of normal genomes. We then segmented the copy-ratio profiles using the circular binary segmentation (CBS) algorithm 68 . Next, we performed allelic copy analysis using reference and alternate counts at germline heterozygous SNP sites. These data allow the identification of copy-neutral LOH events and inference of the contribution of each chromosome to observed copy profiles. We then combined the two data types to derive allelic copy-ratio profiles (Supplementary Fig. 4) .
To determine which observed somatic variants were pathogenic, we first identified events that had a minor allele frequency less than 0.001 in the Exome Aggregation Cohort (ExAC) database and were marked as deleterious by Mutation Assessor. Next, we enriched for mutated genes that were previously implicated in myeloid malignancies. Finally, we compared each mutation's variant classification with expected gene function and selected inactivating mutations for tumor suppressors and activating mutations in regulatory domain hotspots for oncogenes as annotated in the Catalogue of Somatic Mutations in Cancer (COSMIC) database 69, 70 .
To assess tumor contamination of normal tissue (TiN), we applied deTiN (A.N.T.-W., C.S., D.A. Landau, K. Cibulskis and E. Rheinbay et al., unpublished data) using both copy number events and mutations, when available. Briefly, deTiN estimates TiN using evidence for putative somatic events observed in the normal sample ( Supplementary Table 11 ). The contamination estimates were then applied to our single-nucleotide variant (SNV) and indel calls to recover events previously rejected because of an impure germline source.
We were then able to ensure higher sensitivity, even with non-optimal germline samples. We observed distinct differences in TiN content specific to each tissue type (Supplementary Fig. 13 ). Fibroblasts from either bone marrow or skin (n = 4) had the lowest TiN content with a mean of less than 1%. Sixty percent of the buccal samples (n = 10) collected at the time of diagnosis were infiltrated by leukemia cells and had a mean TiN content of 11%, ranging from 0 to 25%. A previous study cast doubt on the use of EBV-immortalized cell lines as a source of germline material in JMML 13 . Consistent with this report, EBV-transformed lymphoblasts from two of six patients with JMML had a TiN of <1%, whereas in four others there was clear involvement of mutations in a clonal fashion. Similarly, cord blood (n = 5) from patients contained >60% TiN in three samples, reflecting the presence of leukemia cells at birth 71 .
To estimate TiN using mutations, deTiN fits the fraction of alternate reads in the normal sample at candidate somatic sites. When samples had fewer than three somatic SNVs identified with our standard mutation calling pipeline, we used alternate and reference allele counts at previously identified canonical events in those samples to build the contamination model. To construct this model, deTiN first calculates the probability that a given candidate mutation is a somatic or germline event over a range of potential TiN levels. Then, we iterate over TiN levels, each time constraining the fit using mutations. We repeat the same process using heterozygous SNPs in regions of allelic imbalance and constrain the estimate using the amount of allelic imbalance observed in the normal sample in relation to the tumor sample. We then combine each of these estimates by adding the likelihood curves.
Next, we use the combined TiN estimate to keep mutation calls from variants that were originally rejected as germline but were actually 1,000 times more likely to be explained by TiN.
Validation.
A customized TruSeq amplicon kit was designed, using the online DesignStudio pipeline (Illumina), that targeted the entire coding regions of 16 genes (ASXL1, CBL, DNMT3A, EZH2, GATA2, JAK3, KRAS, NF1, NRAS, PTPN11, RRAS, RRAS2, RUNX1, SETBP1, SH2B3 and ZRSR2) and covered a total of 49,710 bp with 184 amplicon regions. Libraries prepared from the DNA of each of 91 samples were indexed and subjected to 250-bp paired-end sequencing on the Illumina MiSeq platform, and data from three independent MiSeq runs were combined to generate an average of 761,678 reads/sample (median of 383,391 reads/sample; Supplementary Fig. 14a ). While 95.6% of the total reads passed quality filtering, more than 97.4% of the mapped reads (99.8% mapping rate) were in the targeted regions, providing an average coverage depth of 1,380× across the targeted regions ( Supplementary  Fig. 14b and Supplementary Table 12 ). Hotspots not adequately covered on the MiSeq platform were analyzed by Sanger sequencing. Targeted sequencing data were analyzed as described previously 72 . In brief, after quality trimming, reads from each sample were aligned to the human genome reference sequence (GRCh37/hg19), and the CLC Genomic Workbench (v7.5, CLC Bio) was used for mapping and variant calling. An in-house tool was then used to filter through the variant list, and the consequences of the protein sequence changes resulting from the detected DNA sequence changes were predicted using the ANNOVAR functional annotation tool. Only variants with greater than 5% allelic fraction and at least 8× coverage of the mutated allele were included as a somatic alteration; additional detectable variants are reported for completeness ( Supplementary Table 3 ). DNA methylation analysis. Genomic DNA was bisulfite converted using the EZ DNA Methylation kit (Zymo Research) and processed on Infinium HumanMethylation450 BeadChip arrays (Illumina) according to the manufacturer's protocol. Probe-level signals for individual CpG sites were subjected to both background and global dye bias correction 73 . Probes that mapped to regions with known germline polymorphisms, to multiple genomic loci or to either sex chromosome were filtered out. Two-way unsupervised hierarchical clustering was performed using Euclidean distance and Ward linkage on the 1,486 most variable CpG sites across the cohort, with variability ranked by standard deviation. Four subjects with clonal ASXL1 mutations at diagnosis were included for analysis. An additional seven patients were chosen as controls because they had similar mutational profiles in comparison to the subjects except they did not possess any known genetic mutations in genes for epigenetic regulators (Supplementary Fig. 6 ).
RNA sequencing. RNA was extracted, used to prepare mRNA libraries and sequenced on the Illumina HiSeq platform, resulting in paired 50-nt reads; resulting data were subjected to quality control as previously described 74, 75 . RNA reads were aligned using TopHat. Gene expression was quantified for transcripts corresponding to GENCODE v12 genes using reads per kilobase of transcript per million mapped reads (RPKM). Detection of rearrangements was performed using dRanger as described previously 76 . Fusion detection was performed using TopHat-Fusion.
Analysis of RNA sequencing data. For RNA-seq analysis, paired-end sequencing was performed using the HiSeq platform with a 100-bp read length. Pairedend reads from RNA-seq were aligned to the following four database files using Burrows-Wheeler Aligner (BWA; 0.5.10): (i) the human GRCh37-lite reference sequence, (ii) RefSeq, (iii) a sequence file representing all possible combinations of non-sequential pairs in RefSeq exons and (iv) the AceView database flat file downloaded from the UCSC Genome Browser representing transcripts constructed from human ESTs. The mapping results from databases (ii) to (iv) were translated to human reference genome coordinates. In addition, they were aligned using STAR 2.3.0 to the human GRCh37-lite reference sequence without annotations. A BAM file was constructed by selecting the best alignment among the five mappings. Poor-quality mappings were improved using SIM4 when possible to generate the final BAM file. Coverage was calculated using an in-house pipeline. Structural variation detection was carried out using CICERO, a novel algorithm that uses de novo assembly to identify structural variation in RNA-seq data (Y.L., T. Bo, M. Rusch, J. Easton and K. Boggs et al., unpublished data).
Digital gene expression profiling.
Transcript expression levels were estimated as fragments per kilobase of transcript per million fragments (FPKM); gene FPKM values were computed by summing the transcript FPKM values for each gene using Cuffdiff2 (ref. 77) . A gene was considered to be expressed if the FPKM value was ≥0.5 according to the distribution of FPKM gene expression levels. Genes that were not expressed in any sample were excluded from the final data matrix for downstream analysis.
Sanger sequencing. Sanger sequencing of the discovery cohort including of ASXL1 (p.Tyr591* and p.His630fs), DNMT3A (p.Arg882Cys), EZH2 (p.Val674Leu), GATA2 (p.Asn317Ser), RRAS (p.Gln87Leu), RRAS2 (p.Gln72Leu), RUNX1 (p.Arg349fs), SETBP1 (p.Asp868Asn, p.Gly870Asp and p.Gly870Ser), SH2B3 (p.Gln258*, p.Trp262*, p.Phe390fs, p.Glu400Lys and p.His414_splice) and ZRSR2 (p.Gly179Glu) was performed using the primers listed in Supplementary Table 13 . All mutations were tested in both germline and tumor tissue to determine germline versus somatic acquisition (Supplementary Fig. 15 ). Sequencing was carried out using Hot-Start Polymerase (Promega) and the following PCR conditions: incubation at 95 °C for 2 min; 35 cycles of 94 °C for 45 s, 60 °C for 30 s and 72 °C for 40 s; and incubation at 75 °C for 5 min. Sequences were aligned using CLC software (CLC Bio).
Single-colony analysis. Mononuclear cells were isolated from fresh bone marrow or peripheral blood samples and resuspended in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 2% FBS. Cells were suspended at a concentration of 200,000 cells/ml. The cell suspension (154 µl) was added to a tube containing 1.2 ml of human methylcellulose (R&D Systems Human Methylcellulose Complete Media, HSC003), 15 µl of 100× penicillinstreptomycin, diluted in water, and IMDM to bring the final volume to 1.54 ml. The cytokines used included erythropoietin, granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-3 (IL-3) and stem cell factor (SCF). The solution was vortexed for 15 s and rested for 15 min; 1.1 ml was plated into a 35 × 10 mm Petri dish (BD Falcon, 351008) placed in a 150 × 15 mm Petri dish (BD Falcon, 351058), with another dish containing sterile water, and plates were placed in an incubator at 37 °C with 5% CO 2 . After 14 d, plates were removed from the incubator, and 2 µl of colonies (clusters of 50 cells or more) were plucked under a microscope at 40× magnification and resuspended in 20 µl of TE buffer. PCR amplification was then carried out for each of the mutations using 1 ml of the vortexed colony suspension and the primers listed in Supplementary Table 13 .
Fibroblast cultures. Bone marrow or skin cells were cultured in Chang media (Irvine Scientific, T105), which was changed every 3 d. Cells were split when the fibroblasts became 70% confluent and were collected for DNA extraction using standard methods when the fibroblasts began to have a flattened morphological appearance.
Immunoblotting. Whole-cell extracts were prepared from previously cryopreserved samples in NP-40 lysis buffer supplemented with protease inhibitors. Blots were blocked with 5% BSA in TBS with 0.1% Tween-20 for 1 h at room temperature and probed with primary antibody to LNK (H-129, Santa Cruz Biotechnology) and secondary horseradish peroxidase (HRP)-conjugated antibody (GE Healthcare) for 1 h each. Protein quantification for immunoblots was performed using Image Lab software (v.5.2, Bio-Rad).
Statistical analyses. Data from patients enrolled on AAML0122 were current as of 8 June 2010. Data from the remaining patients were current as of 1 October 2014. The number of somatic alterations at diagnosis, categorized as zero or one versus two or more, was the predictor variable of interest in this analysis. Somatic alterations were defined as pathogenic mutations in genes or monosomy 7. Clinical and biological features were compared between the groups. The significance of observed differences in proportions was tested using the χ 2 test (for categorical variables) or the t test (for continuous variables), and Fisher's exact test was used when data were sparse. The Mann-Whitney test was used to determine the difference in medians. The Kaplan-Meier method 78 was used to estimate the probabilities of event-free survival and overall survival. Event-free survival was defined as the time from diagnosis to first occurrence of relapse, treatment-related mortality or death; overall survival was defined as the time from diagnosis to death. Event-free and overall survival distributions were compared according to the number of somatic alterations at diagnosis using a two-sided log-rank test. Cox proportional hazards models 62 were used to estimate the hazard ratio for defined groups of patients in univariate and multivariate analyses of overall and event-free survival. Relapse incidence was defined as the probability of having a relapse before time t; death without experiencing a relapse was considered a competing event. Cumulative incidence was compared using Gray's test 63 . P values less than 0.05 were considered statistically significant. All statistical analyses were performed using STATA.
